IMM-101 induces protective responses in preclinical models of cancer

Collaborations between Immodulon Therapeutics and academic laboratories in London Universities are yielding new data showing promising therapeutic effects of treatment with IMM-101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) in various preclinical models of cancer.

Preliminary data were presented at the 2013 and 2014 Annual meeting of the Society for Immunotherapy (SITC).


Full Title: Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer.

Journal: Journal of ImmunoTherapy of Cancer

Authors: Androulla Elia, Louise Lincoln, Laura Rosa Brunet and Thorsten Hagemann

DOI: 10.1186/2051-1426-1-S1-P215

Date: 7 November 2013

View poster presented at SITC 2013

Full Title:

Journal: Journal of ImmunoTherapy of Cancer

Authors: Daniel Fowler, Angus Dalgleish and Wai Lu

DOI: 10.1186/2051-1426-2-S3-P54

Date: 6 November 2014

View poster presented at SITC in 2014